Cluster and migraine sufferers are among the most desperate searchers in pain medicine. The pain is real, and clinics market HBOT as a fast-acting fix. The trial record supports a narrow acute-attack effect at best.
This page lays out what the small headache trials actually show. The short version up front: brief acute relief is possible, prevention is not supported, and home oxygen does most of what HBOT might do at a fraction of the cost.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for cluster or migraine |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for headache disorders |
| Insurance coverage | Out-of-pocket at most clinics |
| Typical out-of-pocket | $200-$400 per session |
| Evidence grade | Low — small trials, no prophylactic benefit |
The evidence
Headache HBOT has a narrow but real trial base. Acute cluster attacks have shown response in small studies. Migraine prevention has not.
The Di Sabato and colleagues 1993 Pain trial, PMID 8455970 tested HBOT in 7 patients with episodic cluster headache. Six of seven attacks aborted, and placebo gas had no effect in a separate 6-patient comparison. The trial was small and unblinded.
The Nilsson Remahl and colleagues 2002 Cephalalgia trial ran a double-blind, sham-controlled crossover in active cluster headache. The HBOT arm did not beat sham gas. The trial was the best-designed test for cluster relief and was negative.
The Bennett and colleagues Cochrane review of room-pressure and hyperbaric oxygen for migraine and cluster, 2008, PMID 18646121 pooled the trials. The review found weak signs that HBOT may help acute migraine and possibly acute cluster attacks. The review found no signs of benefit for prevention.
The Bennett and colleagues 2015 Cochrane update, PMID 26709672 extended the same review. The findings did not change. Acute relief possible, prevention not supported.
Small case reports add color but not strength. The trial base has stayed small for over thirty years.
The history of oxygen for cluster headache, Haane 2012 traces the evidence base. High-flow room-pressure oxygen at 12-15 L/min by mask is the standard acute cluster fix. It works in 70-80% of attacks and can be done at home for very little money.
That last point matters. Home oxygen does most of what HBOT might do without the chamber cost or the clinic visit.
The migraine trial record is even thinner. A few small studies suggest a possible perk on acute attacks, and prevention is not supported by any randomized trial.
The American Headache Society guidelines and the American Academy of Neurology guidelines do not list HBOT for cluster or migraine prevention. The listed acute cluster options are home oxygen, sumatriptan, and other proven drugs.
Why people pursue this anyway
Cluster headache is one of the most painful disorders in medicine. Migraine can be disabling for days. The promise of any new option pulls in desperate patients.
Wellness chains such as Restore Hyper Wellness, OxyHealth-equipped clinics, and a long tail of small operators market HBOT for headaches. The pitch leans on the Di Sabato paper from 30+ years ago. The harder Nilsson Remahl trial is rarely mentioned.
The honest gap is that one small unblinded positive trial and one well-designed negative trial are not the same as proof. Headache patients deserve to know that gap.
For deeper context on the marketing-vs-evidence split, see our analysis of institutional silence on HBOT and our FDA-cleared chambers list.
What clinical guidelines say
The American Headache Society does not list HBOT in its acute or preventive cluster headache guidelines. Normobaric oxygen at 12-15 L/min is the listed acute therapy. Sumatriptan is the listed second-line option.
The American Academy of Neurology migraine guidelines do not include HBOT. The European Headache Federation also does not list HBOT for either condition.
UHMS does not include headache disorders on its 14 approved indications list. The official UHMS HBO indications page, 2024 is the source of truth.
The silence from these bodies is not an oversight. It reflects the trial record and the existence of a much cheaper alternative — high-flow normobaric oxygen.
Cost versus evidence
A single HBOT session at a wellness clinic runs $200 to $400. Even an as-needed acute-attack regimen adds up fast.
Compare that to a home oxygen prescription. Insurance often covers normobaric oxygen for cluster headache. The cost difference is in the thousands per year.
That math asks a hard question — why would a patient pay clinic prices for what home oxygen does at near-zero marginal cost?
The framing is not that no patient should try this. The framing is that the evidence and economics both point away from clinic HBOT for headaches.
What to ask your physician
Patients considering HBOT for headache can ask several questions.
What is the FDA status for this use — the answer is "not approved." Have I been offered home oxygen first — the answer should be yes for cluster headache. What does my neurologist think — the answer is usually that proven options come first.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The Di Sabato protocol used medical-grade hard chambers from makers such as Sechrist Industries and Perry Baromedical, not the soft chambers found at most wellness centers.
Distinguishing from FDA-approved uses
Headache sits very differently from approved HBOT uses. The approved list — carbon monoxide poisoning, dive injury, stubborn bone infection, diabetic foot wounds, and ten others — all have decades of backing data.
Our decompression sickness evidence atlas and carbon monoxide poisoning evidence atlas show what real FDA-approved HBOT evidence looks like — multiple independent trials, multi-center designs, and a settled mechanism.
Headache does not have that backing. The honest call is to label it "investigational" and let patients try home oxygen first.
Frequently asked questions
Is HBOT FDA-approved for cluster headache or migraine?
No. The FDA recognizes 14 conditions for HBOT and headache disorders are not among them. The UHMS approved indications list, current 2024, also does not include headache.
What does the Di Sabato 1993 trial actually show?
The trial reported that 6 of 7 cluster attacks aborted with HBOT in unblinded use. It was a small case series. The better-designed Nilsson Remahl 2002 sham-controlled trial did not find a significant advantage for HBOT over placebo gas.
Will Medicare or insurance cover this?
Generally no for HBOT. Medicare and most plans cover home normobaric oxygen for cluster headache, which is the guideline-recommended acute therapy. Clinic HBOT is out-of-pocket.
Can HBOT prevent future cluster cycles?
No randomized trial supports prophylactic HBOT for cluster or migraine. The Cochrane reviews from 2008 and 2015 both concluded that the evidence does not support prevention.
Should I try this before home oxygen?
Most headache specialists would say no. Home normobaric oxygen works in 70-80% of acute cluster attacks, is cheap, and is the recommended first-line acute therapy.
Sources
- Di Sabato and colleagues 1993, PMID 8455970
- Nilsson Remahl and colleagues 2002, Cephalalgia
- Bennett Cochrane 2008, PMID 18646121
- Bennett Cochrane 2015 update
- Haane history of oxygen for cluster 2012
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for headache is an investigational off-label use without FDA approval. Standard cluster headache care including home normobaric oxygen, sumatriptan, and preventive medications remains the guideline-recommended path. Talk to your neurologist or headache specialist before pursuing out-of-pocket HBOT. This page does not diagnose or substitute for professional medical care.